DKA Prevention and Insulin Pumps: Lessons Learned From a Large Pediatric Pump Practice

Elizabeth Ann Doyle1, Stuart Alan Weinzimer2, William Tamborlane2

  • 1Yale University School of Nursing, Orange, Connecticut.

Insights

Diabetic ketoacidosis (DKA) is uncommon in youth using insulin pumps, but often preventable. Education on pump troubleshooting is crucial, especially for teens with high A1C levels, even those using continuous glucose monitors (CGMs).

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Disorders
  • Diabetes Technology

Background:

  • Diabetic ketoacidosis (DKA) remains a significant complication in youth with type 1 diabetes (T1D).
  • Insulin pump therapy and continuous glucose monitors (CGMs) are increasingly used to manage T1D in pediatric populations.
  • Understanding DKA incidence and contributing factors in this cohort is essential for effective prevention strategies.

Purpose of the Study:

  • To report recent incidence data for DKA in young insulin pump users with T1D.
  • To evaluate the impact of CGMs on DKA rates among these patients.
  • To identify common causes of DKA events in this population.

Main Methods:

  • Retrospective chart review of insulin pump users (under 26 years) from December 2019 to June 2021.
  • Analysis of 591 patients, with a focus on DKA event occurrence, severity, and patient characteristics.
  • Comparison of DKA severity between CGM users and non-users.

Main Results:

  • DKA incidence was 3.16 events per 100 patient-years among 591 pump users.
  • Most DKA events occurred in adolescents (85.7% aged 12-19) with high A1C (mean 10.2%) and longer diabetes duration.
  • Pump site failure (57.1%) was the most common cause; CGM use did not significantly alter DKA severity.

Conclusions:

  • DKA events are relatively infrequent in youth using insulin pumps but are often preventable.
  • Reinforced DKA prevention education is vital, particularly for adolescents with elevated A1C levels.
  • Even CGM users require frequent educational reinforcement regarding DKA prevention and pump troubleshooting.
Abstract

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
232
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
258
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.0K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
340
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.7K
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
490